Due tonational shortageof the nebulization solutions, theformulary status of inhaler products has been temporarily adjusted to formulary, restricted to use during the albuterol/Duoneb shortage. Upon shortage resolution, these products willautomatically return to their original formulary status. SeeAlbuterol/Duoneb Shortage Mitigationfor more information. (UpdatedFeb 2023)
ORDERED FORMULATION
THERAPEUTIC INTERCHANGE
albuterol-ipratropium (Combivent Respimat)
CFC free 100 mcg-20 mcg/inh 1 puff
albuterol-ipratropium (DuoNeb)
2.5 mg-0.5 mg/3 mL inhalation solution ONE vial (2.5 mg-0.5 mg)
Reviewed: June 26, 2007 (DuoNeb) and July 23, 2013 (Combivent Respimat) and November 19, 2013 (Combivent Respimat interchange program)
Due to national shortage of the nebulization solutions, the formulary status of inhaler products has been temporarily adjusted to formulary, restricted to use during the albuterol/Duoneb shortage. Upon shortage resolution, these products will automatically return to their original formulary status. See Albuterol/Duoneb Shortage Mitigation for more information. (Updated Feb 2023)
ORDERED FORMULATION
THERAPEUTIC INTERCHANGE
albuterol-ipratropium (Combivent Respimat)
albuterol-ipratropium (DuoNeb)
Reviewed: June 26, 2007 (DuoNeb) and July 23, 2013 (Combivent Respimat) and November 19, 2013 (Combivent Respimat interchange program)